These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37404594)

  • 1. Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease.
    Taliaferro LM; Dodson S; Norton MC; Ofei-Dodoo S
    Explor Res Clin Soc Pharm; 2023 Sep; 11():100295. PubMed ID: 37404594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.
    Wagner AA; Whitner JB; Williams AC; Hirt KL; Miracle TL; Valentino AS
    Innov Pharm; 2023; 14(3):. PubMed ID: 38487386
    [No Abstract]   [Full Text] [Related]  

  • 4. Connecting Patients to Prescription Assistance Programs: Effects on Emergency Department and Hospital Utilization.
    Burley MH; Daratha KB; Tuttle K; White JR; Wilson M; Armstrong K; McPherson S; Selinger S
    J Manag Care Spec Pharm; 2016 Apr; 22(4):381-7. PubMed ID: 27023691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
    Shi L; Wharton MK; Monnette A
    Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Patient Assistance Programs on Hospital Visits in Patients With Chronic Obstructive Pulmonary Disease or Asthma.
    Gallman BN; Huddleston JW; Ray ME; Smith SE
    J Pharm Pract; 2023 Oct; 36(5):1113-1117. PubMed ID: 35428409
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes Outcomes: Comparison of Patient Assistance Programs to 340B Drug Pricing.
    Challen L; Kelso C; Pautler HM; Benanti G
    J Health Care Poor Underserved; 2016; 27(3):1192-8. PubMed ID: 27524761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
    Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
    PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Remote Patient Monitoring Intervention for Patients With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Pre-Post Economic Analysis of the Smart Program.
    Isaranuwatchai W; Redwood O; Schauer A; Van Meer T; Vallée J; Clifford P
    JMIR Cardio; 2018 Dec; 2(2):e10319. PubMed ID: 31758770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a metrics dashboard for monitoring involvement in the 340B Drug Pricing Program.
    Karralli R; Tipton J; Dumitru D; Scholz L; Masilamani S
    Am J Health Syst Pharm; 2015 Sep; 72(17):1489-95. PubMed ID: 26294243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center.
    De La Riva L; Gray E; Braden-Suchy N; Irwin AN
    Am J Health Syst Pharm; 2024 Apr; ():. PubMed ID: 38557600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
    Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
    Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
    Clark BL; Hou J; Chou CH; Huang ES; Conti R
    Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Organizational Sustainability of an Urban Indian Health Clinic With an Innovative Pharmacy Model.
    Gallegos N; Fitzgerald L; Versackas A; Sherer E; Valdez C
    J Prim Care Community Health; 2022; 13():21501319211069750. PubMed ID: 35068248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
    Conti RM; Nikpay SS; Buntin MB
    JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.